The company being acquired specializes in developing next-generation treatments for gout.
"The acquisition of Arthrosi allows us to broaden our pipeline in gout with a clearly differentiated new asset," says Guido Oelkers, President and CEO of Sobi, according to a press release .
Sobi will pay the equivalent of SEK 9.1 billion for the purchase itself and an additional up to SEK 5.3 billion depending on how the company develops.
The deal is expected to be completed in the first half of 2026.
The Wallenberg family's power company Investor is the largest owner of Sobi with 34 percent of the shares, according to Dagens Industri .
